Study of zeprumetosta for advanced skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral medication, zeprumetosta, for people with a type of skin lymphoma (mycosis fungoides or Sézary syndrome) that has come back or not improved after at least one prior treatment. The goal is to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with mycosis fungoides or Sézary syndrome, a type of lymphoma that affects the skin.
- Your disease is at an advanced stage (IIB to IVB) and can be measured by scans or skin exams.
- You have already tried at least one systemic treatment (like radiation to the skin, bexarotene, interferons, or methotrexate) and it didn't work or the disease came back.
- Your liver, kidneys, and blood counts are within acceptable levels.
- You are able to take oral medication and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, zeprumetostat, combined with other treatments for people with a type of lymphoma that has come back or not responded to previous therapy. The goal is to see if these combinations can help control the cancer.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.